Advik Laboratories Ltd Stock Price Today (NSE: ADVIKLA)

Advik Laboratories Ltd

2.08+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Advik Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Advik Laboratories Ltd share price today is 2.08, up +0.00% on NSE/BSE as of 17 September 2026. Advik Laboratories Ltd (ADVIKLA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 3.98 (Cr). The 52-week high for ADVIKLA share price is 2.08 and the 52-week low is 1.57. The company has a Return on Equity (ROE) of -177.51% and a debt-to-equity ratio of 109.84.

Advik Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
2.08
Low
1.90
Volume
1.1K
Change
+4.74%

Advik Laboratories Ltd share price chart: 4.74% return over the past month. 52-week high ₹2.08, 52-week low ₹1.57.

Advik Laboratories Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
2.082.082.082.081.45K (Cr)
1.991.991.991.990.00 (Cr)
1.991.991.991.990.00 (Cr)
1.991.991.991.990.00 (Cr)
1.991.991.991.990.00 (Cr)
1.991.991.991.990.00 (Cr)
1.991.991.991.990.00 (Cr)
1.991.991.991.990.00 (Cr)
1.991.991.991.990.00 (Cr)
1.991.991.991.9919.19K (Cr)

Advik Laboratories Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
2.082.082.082.08+0.00%
1.901.991.901.99+4.74%
1.811.901.811.90+4.97%
1.731.811.711.81+4.62%
1.731.731.731.73+0.00%
1.731.731.731.73+0.00%
1.571.731.571.65+5.10%
1.761.761.601.65-6.25%
1.761.801.681.68-4.55%
1.771.851.761.85+4.52%
1.901.901.761.76-7.37%
2.082.081.991.99-4.33%

Returns & Performance

Poor

Return on Equity (ROE)

-177.51%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-135.87%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Advik Laboratories Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

35.90%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.58%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

16.04%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-9.04%

Net profit growth vs same quarter last year

Revenue Growth (Quarterly YoY)

N/A

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

Good

EPS Growth (5-Year CAGR)

12.20%

Earnings per share growth over 5 years

Good

Net Profit Growth (5-Year CAGR)

12.20%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

109.84x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-1321.38x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-5.62 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Advik Laboratories Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ADVIKLA across key market metrics for learning purposes.

Positive Indicators

0 factors identified

No significant strengths identified in current analysis.

Risk Factors

9 factors identified

Below-Average Return on Equity (-177.51%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-135.87%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

High Price-to-Book Ratio (58.03x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Elevated Debt Levels (D/E: 109.84)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (-1321.38x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Liquidity Concerns (Current Ratio: 0.23)

Observation: Current assets may not adequately cover short-term liabilities.

Analysis: Current ratio <1.0 raises working capital concerns.

Negative Free Cash Flow (₹-5.62 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 0.58%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Advik Laboratories Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Advik Laboratories Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
0/100
2
₹3.98
-177.51%
Poor
-135.87%
Poor
109.8
Poor
12.20%
Good
0.00%
66.4/100
1840
₹441471.20
36.5
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9322
₹247033.00
84.6
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4966
₹168062.31
79.3
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1119
₹111686.18
24.9
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1366
₹110352.31
32.7
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1969
₹106375.23
97.2
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
41/100
1166
₹97319.25
30.1
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
24.6/100
1680
₹96655.69
26.2
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2095
₹95793.88
17.3
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2280
₹94164.00
46.1
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Advik Laboratories Ltd Quarterly Performance

Latest quarterly metrics for ADVIKLA — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

N/A

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-9.04%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

12.20%

Compounded annual net profit growth over 5 years

Advik Laboratories Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ADVIKLA — calculated from daily price history

100RSI 14
Overbought — RSI 100

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
2
▲ Price above SMA 50 — Short-term bullish
30-Day Avg Volume
1K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Advik Laboratories Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Advik Laboratories Ltd (ADVIKLA) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Advik Laboratories Ltd

Loading latest quarterly results...

About ADVIKLA (Advik Laboratories Ltd)

Advik Laboratories Ltd is a research-driven pharmaceutical company dedicated to developing, manufacturing, and marketing innovative and high-quality medicines. Focusing on therapeu...tic areas with unmet medical needs, Advik Laboratories strives to improve patient outcomes and enhance the quality of life for individuals worldwide. The company's state-of-the-art research and development facilities are staffed by a team of experienced scientists and researchers who are committed to discovering and developing novel drug formulations. Advik Laboratories adheres to the highest ethical standards and regulatory requirements, ensuring the safety and efficacy of its products. With a strong emphasis on innovation, quality, and patient-centricity, Advik Laboratories is poised to make a significant impact on the global healthcare landscape. The company's robust product portfolio encompasses a wide range of therapeutic categories, including cardiovascular diseases, diabetes, oncology, and infectious diseases. Advik Laboratories leverages advanced technologies and innovative drug delivery systems to develop differentiated products that address specific patient needs. The company's manufacturing facilities are equipped with advanced technology and adhere to strict quality control measures to ensure that all products meet the highest standards of purity, safety, and efficacy. Advik Laboratories is committed to providing affordable and accessible medicines to patients around the world, partnering with healthcare professionals and organizations to improve access to care and promote better health outcomes. Advik Laboratories has established a strong global presence, with a network of distributors and partners in key markets around the world. The company's commitment to innovation, quality, and patient-centricity has earned it a reputation as a trusted and reliable partner in the pharmaceutical industry. Advik Laboratories is constantly seeking to expand its product portfolio and explore new therapeutic areas to address emerging healthcare needs. The company is dedicated to improving the lives of patients worldwide through the development and delivery of innovative and high-quality medicines. Advik Laboratories is driven by a passion for science, a commitment to innovation, and a desire to make a positive impact on global healthcare.

Company Details

Symbol:ADVIKLA
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Peeyush Kumar Aggarwal
Chairman of the Board & MD
Mr. Manoj Kumar Bhatia
Chief Financial Officer
Ms. Pooja Chuni
Compliance Officer & Company Secretary

ADVIKLA Share Price: Frequently Asked Questions

What is the current share price of Advik Laboratories Ltd?

Advik Laboratories Ltd (ADVIKLA) trades at ₹2.08 on NSE and BSE. Market cap ₹3.98 (Cr). Educational data only.

What is the P/E ratio of Advik Laboratories Ltd?

Advik Laboratories Ltd has a P/E of N/Ax vs industry average 34.89x.

What is the Bull Run score for Advik Laboratories Ltd?

Advik Laboratories Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.

Does Advik Laboratories Ltd pay dividends?

Advik Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Advik Laboratories Ltd?

Advik Laboratories Ltd has ROE of -177.51%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Advik Laboratories Ltd?

Advik Laboratories Ltd has debt-to-equity of 109.84.

Is Advik Laboratories Ltd a good investment?

Bull Run gives Advik Laboratories Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.